Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Korea's Samsung Electronics On Manhunt For Biosimilar Talent As Local Companies Keep Wary Eye On Competition

This article was originally published in The Pink Sheet Daily

Executive Summary

Industry officials say about 10 biosimilar R&D experts from leading biopharmas have been recruited by Samsung, which sees the potential market for biosimilars and is moving beyond its traditional territory of electronics products.

You may also be interested in...



Korea's Celltrion Cuts Deal With Perrigo To Sell Its Biosimilars In Israel

SEOUL - As part of its bid to stretch out for more global sales for a range of antibody therapeutic biosimilars, Celltrion has signed a deal with Perrigo to market its products in Israel

Korea Moves To Help Samsung Electronics Create Consortium in Biosimilars

SEOUL - As the South Korean government accelerates its drive to get local producers of biosimilars globally competitive, the Ministry of Knowledge Economy is setting the stage for Samsung Electronics to become a giant in the emerging biosimlars market

Korean Celltrion Gears Up To Produce Biosimilar Herceptin, Remicade, Erbitux; Proposes Barter System In Developing Regions

SEOUL - "Celltrion is currently developing a total of nine blockbuster antibody therapeutic biosimilars, and we are preparing for the launch of three biosimilars for markets not protected with patent rights," Kim Yong-Joong, Celltrion's strategic planning assistant manager, told PharmAsia News

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS070412

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel